JPRN-jRCTs031190076招募中3 期
JCOG1801: A phase III randomized controlled trial comparing surgery plus adjuvant chemotherapy with preoperative chemoradiotherapy followed by surgery plus adjuvant chemotherapy for locally recurrent rectal cancer - RC-SURVIVE study
适应症
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 发起方
- Ito Masaaki
- 入组人数
- 110
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 <= 80age old（—）
- 性别
- All
入选标准
- •(1) Pathologically proven adenocarcinoma or adenosquamous carcinoma using the resected specimen of the initial rectal cancer or the endoscopic biopsy from the initial rectal cancer.
- •(2) The main tumor location of the initial rectal cancer is RS, Ra,Rb,or P.
- •(3) The following treatment was performed for the initial rectal cancer, and judged as R0/1 or ER0/1 in pathological diagnosis.
- •(i) Rectal resection (with or without lymph node dissection).
- •(ii) Local resection.
- •(iii) Endoscopic resection.
- •(4) The patients who had distant metastasis when or after treated for the initial rectal cancer, and radical surgical resection or radical radiotherapy was performed more than 168 days before registration is eligible.
- •(5) Diagnosed as reccurent rectal cancer by the following modality after treatment for the initial rectal cancer.
- •(i) The reccurnet lesion is pathologically diagnosed.
- •(ii) Diagnosed as local reccurence by more than two modality from contrast-enhanced CT, MRI, or PET.
- •(iii) Chronological progression of lesion is obseved by more than one modality from contrast-enhanced CT, MRI, or PET.
- •(6) The main tumor location is diagnosed within pelvis by contrast-enhanced CT and MRI if reccurent lesion is multiple, or reccurent lesions spread outside of pelvis continuously.
- •(7) Not the locally recurrent rectal cancer with any following condition.
- •(i) Judged as resectable endoscopically.
- •(ii) Diagnosed as depth of invasion within MP by contrast-enhanced CT, MRI, or PET in case of recurrence inside of intestine
- •(iii) Solitary ovary metastasis.
- •(iv) Reccurence of common iliac lymph node alone.
- •(8) Locally recurrent rectal cancer is judged as resectable, all of the following conditions must be fulfilled:
- •(i) No distant metastasis on contrast-enhanced CT (cM0).
- •(ii) Judged as estimated CRM>0 mm.
- •(iii) No need of leg amputation.
- •(iv) Able to preserve the first sacral nerve.
- •(9) No prior surgery for recurrent rectal cancer.
- •(10) No prior pelvic irradiation for any malignancies.
- •(11) The patient who had received systemic chemotherapy for any malignancies and was more than 14 days after the final administration is eligible.
- •(12) Age at registration is of 20 to80 years old.
- •(13) ECOG Performance status is 0 or 1.
- •(14) Measureable lesion is not mandatory.
- •(15) Sufficient oral intake.
- •(16) Sufficient organ function.
- •(i) Neutrophil count >= 1,500 /mm3
- •(ii) Hemoglobin >= 9.0 mg/dl
- •(iii) Platelet count >= 100,000 /mm3
- •(iv) Total Bilirubin =< 2.0 mg/dL
- •(v) AST =< 100 U/L
- •(vi) ALT =< 100 U/L
- •(vii) Cr =< 1.5 mg/dL
- •(17) Open surgery, laparoscopic surgery, or robotassisted surgery will be performed.
- •(18) Witten informed consent is obtained.
排除标准
- •(1) Synchronous or metachronous (within 5 years) malignancies except cancer with 5-year relative survival rate of 95% or more such as carcinoma in situ, intramucosal tumor, or early stage cancers.
- •(2) Infections which needs systemic treatment.
- •(3) Body temperature is higher than 38 degrees centigrade at registration.
- •(4) Female during pregnancy, within 28 days of postparturition, or during lactation. Men with partners anticipating conception in the near future.
- •(5) Severe psychological disease.
- •(6) Continuous systemic corticosteroid or immunosuppressant treatment.
- •(7) Uncontrollable diabetes mellitus.
- •(8) Uncontrollable hypertension.
- •(9) Unstable angina pectoris, or history of myocardial infarction within 6 months.
- •(10) Uncontrollable valvular disease, dilated cardiomyopathy, or hypertrophic cardiomyopathy.
- •(11) Positive HBs antigen.
- •(12) Positive HIV antibody.
- •(13) Interstitial pneumonia, pulmonary fibrosis, or severe emphysema on chest CT.
研究者
相似试验
招募中
3 期
JCOG1904: A randomized controlled phase III trial of comparing local field with additional prophylactic irradiation in chemoradiotherapy for clinical-T1bN0M0 esophageal canceresophageal cancerJPRN-jRCTs031200067TSUSHIMA Takahiro176
招募中
3 期
JCOG1905: A randomized controlled phase III trial on continued or paused PD-1 pathway blockade for patients with advanced renal cell carcinomaadvanced renal cell carcinomaJPRN-jRCT1031200071MATSUMOTO Takashi250
招募中
3 期
JCOG2011: A randomized controlled phase III trial for confirming superiority of local radiotherapy added to anti-androgen therapy for prostate cancer patients with high volume metastasis sensitive to hormone therapyhigh volume metastatic prostate cancerJPRN-jRCT1031220676KAMOTO Toshiyuki440
招募中
3 期
JCOG2207: A phase III randomized controlled trial comparing total mesorectal excision and lateral lymph node dissection plus adjuvant chemotherapy with total neoadjuvant therapy followed by total mesorectal excision and selective lateral lymph node dissection for the patients with locoregionally advanced low rectal cancerRectal cancerJPRN-jRCTs031230415OHUE Masayuki420
进行中（未招募）
3 期
JCOG1314: A randomized controlled phase III study comparing docetaxel, CDDP and 5-FU with CDDP and 5-FU in patients with metastatic or recurrent esophageal canceresophageal cancerJPRN-jRCTs031180143TSUBOSA Yasuhiro240